22613-99-6 Usage
Description
trans-2-(Hydroxymethyl)-1-phenylcyclopropanecarboxylic acid, also known as (1R,2R)-2-(Hydroxymethyl)-1-phenylcyclopropanecarboxylic Acid, is an organic compound that is synthesized and used in the pharmaceutical industry. It is characterized by its unique cyclopropane ring structure and hydroxymethyl group, which contribute to its specific properties and applications.
Uses
Used in Pharmaceutical Industry:
trans-2-(Hydroxymethyl)-1-phenylcyclopropanecarboxylic acid is used as an impurity in the synthesis of Milnacipran (M344600) for its role in the development of an antidepressant medication. Milnacipran is a selective norepinephrine and serotonin reuptake inhibitor, which is approved for the management of fibromyalgia. The presence of this compound in the synthesis process is crucial for the effectiveness of the final product, as it contributes to the overall chemical structure and activity of the antidepressant.
Check Digit Verification of cas no
The CAS Registry Mumber 22613-99-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,6,1 and 3 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 22613-99:
(7*2)+(6*2)+(5*6)+(4*1)+(3*3)+(2*9)+(1*9)=96
96 % 10 = 6
So 22613-99-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H12O3/c12-7-9-6-11(9,10(13)14)8-4-2-1-3-5-8/h1-5,9,12H,6-7H2,(H,13,14)/t9-,11-/m0/s1
22613-99-6Relevant articles and documents
Preparation method of levomilnacipran diastereoisomer
-
Paragraph 0045; 0046, (2019/05/08)
The invention provides a preparation method of a levomilnacipran diastereoisomer. The preparation method comprises the following steps: taking benzyl cyanide and R-epichlorohydrin or S-epichlorohydrinas starting materials, performing cycloalkylation on th
PROCESS FOR THE PREPARATION OF (1S,2R)-MILNACIPRAN
-
, (2016/06/01)
The invention relates to a process for the preparation of Levomilnacipran, a compound useful in the treatment of depression, comprising the following steps: a) directly converting the enantiomerically enriched form of alcohol (D) into the enantiomerically enriched form of the phthalimido derivative (C) by treatment with phthalimide in the presence of a trialkyl or triarylphosphine and of a dialkyl azodicarboxylate, formula (I) wherein the amount of phthalimide is comprised between 1 and 1.3 equivalents with respect to the molar amount of alcohol (D) used, and the amounts of both the phosphine and the azodicarboxylate are comprised, independently from each other, between 1 and 1.5 equivalents with respect to the molar amount of alcohol (D) used; b) deblocking the enantiomerically enriched form of the phthalimido derivative (C) to obtain Levomilnacipran, formula (II).
